AIM Genetic Test for Cats Launches in South Korea

Greycoat Research, a company specializing in feline kidney care grounded in AIM research, has introduced its AIM Test kit in South Korea. Plans are in place to roll out the test in the United States and Japan. The AIM Test examines a specific variant in a cat's AIM gene, offering genetic insights that can guide kidney care. Owners can gather an oral cell sample from their cat and send it for testing.

They then receive a report detailing the results, accompanied by a care guide that considers the cat's genetic traits. The service also provides real-life examples of care for cats with the variant. AIM, a protein crucial for clearing cellular debris from the kidneys and aiding recovery after injury, was found in 66% of 1,000 cats studied in a 2026 research by Washington State University.

Greycoat Research aims to expand the AIM Test by developing kidney care consultation services that factor in each cat's genetic makeup and current health status. Additionally, the company is conducting a clinical study in South Korea, enrolling 60 cats over 28 days, including both healthy cats and those with stage 1–3 chronic kidney disease.

This study compares kidney and liver markers and the expression of genes related to inflammation and metabolism before and after a feeding period, incorporating AIM genetic testing. Greycoat Research also plans a longer-term study where cats will receive its kidney care products for a year to assess the products' impact on maintaining or improving kidney function over time.

CEO Claire Yun stated that the goal is to transform genetic information and clinical research into personalized kidney care suited to each cat's health needs.